APA (7th ed.) Citation

AB, P., JA, W., PK, M., K, D., SA, I., NP, K., . . . R, L. (2024). Respiratory syncytial virus (RSV) vaccine effectiveness against RSV-associated hospitalisations and emergency department encounters among adults aged 60 years and older in the USA, October, 2023, to March, 2024: A test-negative design analysis. Lancet (London, England), 404(10462), 1547. https://doi.org/10.1016/S0140-6736(24)01738-0

Chicago Style (17th ed.) Citation

AB, Payne, et al. "Respiratory Syncytial Virus (RSV) Vaccine Effectiveness Against RSV-associated Hospitalisations and Emergency Department Encounters Among Adults Aged 60 Years and Older in the USA, October, 2023, to March, 2024: A Test-negative Design Analysis." Lancet (London, England) 404, no. 10462 (2024): 1547. https://doi.org/10.1016/S0140-6736(24)01738-0.

MLA (9th ed.) Citation

AB, Payne, et al. "Respiratory Syncytial Virus (RSV) Vaccine Effectiveness Against RSV-associated Hospitalisations and Emergency Department Encounters Among Adults Aged 60 Years and Older in the USA, October, 2023, to March, 2024: A Test-negative Design Analysis." Lancet (London, England), vol. 404, no. 10462, 2024, p. 1547, https://doi.org/10.1016/S0140-6736(24)01738-0.